
About Enable Injections
Enable Injections is a Healthcare company based in Cincinnati (United States) founded in 2010 by Mike Hooven. Enable Injections has raised $334.27 million across 11 funding rounds from investors including Cincinnati Children’s, Grosvenor Capital Management and Sanofi. The company has 185 employees. Its chief executive, as recorded, is Mike Hooven. Its website enableinjections.com draws about 10 thousand monthly visits. Enable Injections offers products and services including enFuse Wearable, enFuse Transfer Systems, enFuse Smart Technology, and Empaveli. Its focus areas include Life Sciences, Drug Delivery, Patches and Microneedle Patch. Its competitors include Micron Biomedical, Zosano Pharma and SkinJect; 3 of its 3 listed competitors have raised funding.
Company details
Provider of a wearable drug delivery solution. The companys drug delivery device include enFuse for injectable therapies which enables a range of flexible delivery options for patients and healthcare providers, including a range of viscosities, volumes, delivery times, and sites for administration.
- Headquarters Cincinnati, United States
- Employees 185
- Founders Mike Hooven
- SectorsHealthcare
- Website enableinjections.com
- Social LinkedIn X Facebook Instagram
- Legal Name Enable Injections
- Total Equity Funding$334.27M (USD)
in 11 rounds
- Latest Funding Round$30M (USD), Series C
Jan 2026
- InvestorsCincinnati Children’s
& 11 more
- Employee Count185
Products & Services of Enable Injections
Enable Injections offers a comprehensive portfolio of products and services, including enFuse Wearable, enFuse Transfer Systems, enFuse Smart Technology, and Empaveli.
Wearable device for hands-free subcutaneous medication delivery.
Systems for transferring medications in wearable formats.
Intelligent features for monitoring and administering drugs.
Wearable injector for specific drug therapies.
Funding Insights of Enable Injections
Enable Injections has successfully raised a total of $334.27M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $334.27M
- Total Rounds 11
- Last Round Series C — $30M
- Investors Count 12
Latest 10 of 11 funding rounds of Enable Injections with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | $30M | Series C | – | – | |
| Jan 2022 | $215M | Series C | – | Magnetar | |
| Sep 2020 | $25M | Debt – Conventional | – | – | |
| Oct 2018 | $50M | Series B | – | Sanofi | |
| Nov 2016 | $30M | Series A | – | ORI Capital | |
| Aug 2016 | $2M | Series A | – | – | – |
| Aug 2016 | $5M | Series A | – | – | – |
| Apr 2016 | $2M | Seed | – | – | – |
| May 2015 | $247,250 | Seed | – | – | – |
| Jun 2014 | $22,925 | Seed | – | – | – |
12 investors in total: 12 institutional.
Investors in Enable Injections
Enable Injections has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Cincinnati Children’s, Grosvenor Capital Management and Sanofi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Magnetar Capital is engaged in alternative asset management. | magnetar.com | Evanston, United States | ||
Private fund focused on debt and equity investments in real estate and multiple sectors | 1762 | barings.com | London, United Kingdom | |
Early-stage sector-agnostic VC firm investing in geographies such as the US | ohioinnovationfund.com | Columbus, United States | ||
CincyTech is engaged in venture capital investments for innovative startups. | cincytechusa.com | Cincinnati, USA | ||
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
A venture capital firm focused on early-stage biotech investments. | 2015 | ori-capital.com | Hong Kong, Hong Kong | |
Multi-strategy hedge fund and fund of funds focused on multiple sectors | 1971 | gcmgrosvenor.com | Chicago, United States | |
Global investment manager employing quantitative strategies and advanced technology platforms. | 2014 | squarepoint-capital.com | New York, United States | |
Pediatric healthcare services are delivered through a hospital chain. | 1883 | cincinnatichildrens.org | United States | |
| cintrifuse.com |
Investor details for Enable Injections
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Enable Injections
24 people are tracked at Enable Injections (13 in leadership, 7 in board & advisors, 4 in team); the tracked headcount is 185.
| Name | Role | Group |
|---|---|---|
Mike Hooven | Founder & CEO | Leadership |
Matthew J. Huddleston | EVP, Business Development, & CTO | Leadership |
Eileen Rogers | SVP, Program General Manager | Leadership |
Michael D. Hooven | President & CEO | Leadership |
Mike H. | Director Of Supply Chain | Leadership |
Tim Flaherty | EVP & CFO | Leadership |
Russ Pagano | VP, Quality & Regulatory Affairs | Leadership |
Gwendolyn Payne | Director Of Regulatory Affairs | Leadership |
Jeff Kaufhold | Director Of Quality Assurance | Leadership |
Greg Etter | Vice President Of Engineering And Automation | Leadership |
Baret Kilbacak | Associate Director, Quality Engineering | Leadership |
Jessica Byerly | Senior Director Human Resources | Leadership |
Katie Petry McDonnell | Senior Director, Program Management | Leadership |
Nigel Sheail | Director | Board & advisors |
Richard J. D’Augustine | Director | Board & advisors |
John Rice | Director | Board & advisors |
Simone Song | Director | Board & advisors |
John DeFord | Director | Board & advisors |
Jim Collins | Director | Board & advisors |
Beckie Robertson | Director | Board & advisors |
4 more people are available in the full profile.
Complete people profiles for Enable Injections
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Enable Injections
3 dated milestones of Enable Injections across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Enable Injections is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $30.0M.
Competitors of Enable Injections
Enable Injections has 3 listed competitors in our database, 3 of them funded. They include Micron Biomedical, Zosano Pharma and SkinJect.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| micronbiomedical.com | 2014 | Atlanta, United States | $33M | 11 | Microneedle patches are developed for vaccine and drug delivery. | |
| zosanopharma.com | 2006 | Fremont, United States | $147.16M | 40 | Develops innovative transdermal drug delivery technologies for various therapeutic applications. | |
| skinjectpatch.com | 2015 | Pittsburgh, United States | $3.4M | Dissolvable microneedle patches for non-melanoma skin cancer treatment are developed. |
Detailed competitors of Enable Injections
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Enable Injections
The website of Enable Injections (enableinjections.com) receives about 10.3K visits a month.
- Monthly visits10.3K
▲ 49.1% vs previous month
Websites whose visitors overlap most with Enable Injections. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ondrugdelivery.com | 100% | #833,579 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Enable Injections (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Enable Injections
Complete news archive for Enable Injections
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enable Injections
Enable Injections was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Enable Injections is headquartered in Cincinnati, United States. It is registered at Cincinnati, Ohio, United States.
Mike Hooven is the CEO of Enable Injections, as recorded in our data. They have also founded this company.
Enable Injections is a funded company, having raised a total of $334.27M across 11 funding rounds to date. The company's 1st funding round was a Seed of $22.93K, raised on Apr 2011.
Enable Injections has 185 employees.
Provider of a wearable drug delivery solution. The companys drug delivery device include enFuse for injectable therapies which enables a range of flexible delivery options for patients and healthcare providers, including a range of viscosities, volumes, delivery times, and sites for administration.
Enable Injections's top competitors include Micron Biomedical, SkinJect and Zosano Pharma.
Enable Injections offers enFuse Wearable, enFuse Transfer Systems, enFuse Smart Technology, and Empaveli.
Enable Injections has 12 investors. Key investors include Cincinnati Children’s, Grosvenor Capital Management, Sanofi, Barings, and Oxford Finance.
Enable Injections operates through Enable Injections.
